Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

BACKGROUND: There is increased recognition that cancers of the upper GI tract comprise distinct epidemiological and molecular entities. Erlotinib has shown activity in patients with adenocarcinoma of the oesophagus/gastro-oesophageal junction (GEJ), but not in distal gastric cancer. mFOLFOX6 is one...

Descripción completa

Detalles Bibliográficos
Autores principales: Wainberg, Z A, Lin, L-S, DiCarlo, B, Dao, K M, Patel, R, Park, D J, Wang, H-J, Elashoff, R, Ryba, N, Hecht, J R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171005/
https://www.ncbi.nlm.nih.gov/pubmed/21811258
http://dx.doi.org/10.1038/bjc.2011.280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171005/
https://www.ncbi.nlm.nih.gov/pubmed/21811258
http://dx.doi.org/10.1038/bjc.2011.280

Ejemplares similares